NEW YORK (GenomeWeb News) – Randox Laboratories has agreed to a non-exclusive license for Seegene's technology for use with its biochip array platform, Seegene said today.
The agreement will give Randox access to Seegene's Dual Priming Oligo technology, which it will use to develop high-throughput diagnostic screening panels to detect a variety of pathogens that cause either respiratory or sexually transmitted diseases from one sample.
Randox's Biochip Array Technology is used to detect a panel of related biological markers. The panels include protein biochips for detecting antigens, DNA biochips for mutation, SNP studies and RNA expression profiling.
Financial terms of the agreement were not released.